FDA Approves Inqovi With Venetoclax for AML

Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology) with venetoclax for newly diagnosed acute myeloid leukemia (AML) in adults who are 75 years or older, or who are ineligible for intensive induction chemotherapy. The company noted that the treatment offers “an alternative to parenteral hypomethylating agent–based regimens that require frequent clini